Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methadone vs Morphine for Adenocarcinopathic Pain
NCT05325164Phase 3Withdrawn
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Sep 2022
- Primary completion
- Aug 2023
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial of methadone in cancer pain and Adenocarcinoma, sponsored by Ottawa Hospital Research Institute. Primary endpoint: Pain control at 2 weeks. Planned start Sep 2022; status: withdrawn.
02
Drugs
methadone
03
Conditions
cancer painAdenocarcinoma
Beyond the preview
Go deeper on NCT05325164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05325164.